Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab Combinations With Nivolumab + Linrodostat or Nivolumab + Ipilimumab in Advanced Solid Tumors
2023-508207-21-00Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label trial of relatlimab in Non-hematologic malignancy (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of clinical laboratory test abnormalities, Number of Adverse Events (AEs) and 6 more. Started Mar 2024; status: completed.
02
Drugs
relatlimab
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2023-508207-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508207-21-00.